Mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-16. Anything still debated is marked as such rather than presented as settled.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
== Into a vacuum == Effusion from an equilibrated container into outside vacuum can be calculated based on kinetic theory. The number of atomic or molecular collisions with a wall of a container per unit area per unit time (impingement rate) is given by:
In April 2019, the Minister of Public Works announced that a list of potential sites had been drawn up. In 2020, it was suggested that moving parliament to Pretoria would save R650 million per year. In January 2022, a fire broke out at the Houses of Parliament building in Cape Town causing severe damage to the session rooms of both the National Council of Provinces and the National Assembly. The 2022 State of the Nation Address was held at Cape Town City Hall and subsequent meetings of the National Assembly will be held at the Good Hope Chamber. The Good Hope Chamber has previously been used for committee meetings of the National Assembly and has a seating capacity of 170, reduced to 70 during COVID-19 precautions. The National Assembly has 400 members. Subsequently, to enable a more permanent venue during the rebuild of the Houses of Parliament, Minister of Public Works and Infrastructure Dean Macpherson oversaw major enhancements of the existing Nieuwmeester Dome, which were installed to suit Parliamentary sittings. The dome was built over a parking lot in Roeland Street, close to the Houses of Parliament. It served as the site of the 2026 State of the Nation debates. In February 2026, Secretary to Parliament Xolile George announced that the Parliamentary rebuild would be completed in December 2026.
Oral: Capsules: Prometrium (100 mg, 200 mg, 300 mg) Vaginal: Tablets: Endometrin (100 mg); Gels: Crinone (4%, 8%) Intramuscular injection: Oil: Progesterone (50 mg/mL) A 25 mg/mL concentration of progesterone oil for intramuscular injection and a 38 mg/device progesterone intrauterine device (Progestasert) have been discontinued. An oral combination formulation of micronized progesterone and estradiol in oil-filled capsules (brand name Bijuva) is marketed in the United States for the treatment of menopausal symptoms and endometrial hyperplasia. Progesterone is also available in unregulated custom preparations from compounding pharmacies in the United States. In addition, transdermal progesterone is available over-the-counter in the United States, although the clinical efficacy of transdermal progesterone is controversial.
Sources: en.wikipedia.org
In September 2008, several companies, including Nestlé, were implicated in a scandal involving milk and infant formula which had been adulterated with melamine, leading to kidney stones and other kidney failure, especially among young children. By December 2008, nearly 300,000 people had become ill, with more than 50,000 infant hospitalizations and six infant deaths. In a study published in the New England Journal of Medicine, it was reported that melamine exposure increased the incidence of urinary tract stones by seven times in children. Melamine may have been added to fool government protein content tests after water was added to fraudulently dilute the milk. Because of melamine's high nitrogen content (66% by mass versus approximately 10–12% for typical protein), it can cause the protein content of food to appear higher than the true value. Officials estimate that about 20% of the dairy companies tested in China sell products tainted with melamine. On January 22, 2009, three of those involved in the scandal (including one conditional sentence) were sentenced to death in a Chinese court. In October 2008, "Select Fresh Brown Eggs" exported to Hong Kong from the Hanwei Group in Dalian in northeastern China were found to be contaminated with nearly twice the legal limit of melamine.
== Legacy == Robert Swanson's legacy can still be found to this day through the company he cofounded and led. Genentech continues to develop and produce therapeutic drugs, and some of his policies, such as allowing company scientists to publish, are still in place. Genentech scored many firsts under Swanson's leadership, such as developing the first drug produced via genetic engineering, being the first biotechnology company to go public, and being the first biotechnology company to sell its own drug. These accomplishments have earned Genentech, and Swanson, a place in the history of the biotechnology industry.
== Health hazards == Several chemical substances have been found to be effective in skin whitening, but some have been proven or suspected to be toxic. This includes compounds containing mercury, which can cause neurological and kidney problems. These products also contain collagen, which can be harmful to the skin. It is present in day creams and beauty masks. Collagen is an insoluble fibrous protein that is too large to penetrate the skin, thus it can clog pores. The use of these products can be hazardous to health, potentially causing acne, stretch marks, skin cancer, hypertension, or diabetes, especially when the product contains hydroquinone, mercury, cortisone, or vitamin A. Allergic reactions or undesirable effects, such as uneven hyperpigmentation or patchy depigmentation, can also occur. Among the ingredients, hydroquinone is also commonly found and is responsible for multiple side effects. It can interfere with the reagents used in capillary blood glucose meters, artificially raising blood glucose levels. In 1997, in Paris, the French police dismantled a network involved in the illegal trafficking of skin lightening products, primarily targeting Congolese migrants. Such products represent a significant market despite their health risks. Users resort to preparations containing mercury or bleach, or products containing corticosteroids or quinine. The Saint-Louis Hospital in Paris had to establish a specialized department to deal with the skin disorders caused by skin bleaching.
Lastly, the sixth variant (K5R_I10H_F12W) was developed by combining the amino acid substitutions of the first and second variants. Moreover, researchers from the Clemens-Schöpf Institute of Organic Chemistry and Biochemistry and Helmholtz-Institute for Pharmaceutical Research Saarland, developed potent synthetic human matriptase-1 inhibitors based on a different SFTI-1 variant, SDMI-1. SFTI-1 derived matriptase inhibitor-1 (SDMI-1) was previously developed by replacing residue 10 of SFTI-1 (isoleucine, I) with arginine (R) and residue 12 (phenylalanine, F) with histidine (H). Further modifications of SDMI-1 resulted in synthetic matriptase-1 inhibitors with improved inhibitory activity, matriptase binding, and inhibition potency. The SDMI-1 variant that resulted in enhanced inhibitory activity was developed by replacing residue 1 of SDMI-1 (glycine, G) with lysine (K) and by keeping it as a monocyclic structure. The SDMI-1 variant that resulted in improved matriptase binding was created by using the same amino acid substitutions of the previously mentioned SDMI-1 variant and by attaching a bulky fluorescein moiety to the side chain of lysine. Lastly, the SDMI-1 variant that had enhanced inhibition potency was developed by applying the same amino acid substitutions of the previous variants, cleaving the proline-aspartic acid sequence found at the C-terminus (PD-OH), and by making it a bicyclic compound via tail-to-side-chain cyclization.
Sources: en.wikipedia.org
== Etymology == In Old English, an alcoholic beverage made from apples was simply called æppelwīn ("apple wine"). The word cider is first mentioned in Middle English in biblical use as sicer, ciser ("strong drink", "strong liquor") in the 13th century and as sither(e) / cidre "liquor made from the juice of fruits" → "beverage made from apples" in the 14th century. It was probably first borrowed from Old French primitive form sizre "fermented beverage" (Eadwine Psalter, LXVIII, 14) and then from another younger French form cistre, later sidre, cidre "beverage made from fruits". The specific meaning "fermented beverage from apples" appears in Old French for the first time by the Norman chronicler Wace in 1130 / 1140 (Wace, conception de Nostre Dame). The Old French word *cisre (sizre) is from Gallo-Romance *cisera found in Medieval Latin by the English author Alexander Neckam (Neckam, De nominibus utensilium). It is an altered form of Church Latin sicera "fermented drink", itself borrowed from Greek sīkéra, ultimately from Hebrew šēkār, "intoxicating liquor". The cognates in the different Romance languages : Spanish, Portuguese sidra, Italian sidro, etc., in the Germanic languages : German Zider, etc. are all from French and Breton chistr, Welsh seidr (through an English form) probably too. By the 19th century, in the United States, cider referred to the expressed juice of apples, either before fermentation as sweet cider, or after fermentation, a hard cider.
==== Anticoagulants ==== Anticoagulants are considered more aggressive than antiplatelet drugs. Anticoagulants work by interfering with various clotting factors to lengthen the time for coagulation. This can be achieved by either reducing the formation of bioactive clotting factors or accelerating the inactivation of clotting factors.
== Proto-Hassuna == This period denotes a higher use of ceramics than with the pre-proto-Hassuna period. The site of Umm Dabaghiyah (de:Umm Dabaghiyah-Sotto-Kultur), in the same area of Iraq, is believed to have the earliest pottery in this region, and is sometimes described as a 'Proto-Hassuna culture' site. Other related sites in the area are Sotto and Yarim Tepe I, having 585 recorded ceramic fragments. They were found by archaeologist A.A. Bobrinsky. Another pre-Hassuna or proto-Hassuna site in Iraq is Tell Maghzaliyah. Yet another site with proto-Hassuna pottery is Ginnig. The time frame for this period was about 6700-6300 BC.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.